This study is being conducted to determine how well participants with your type of cancer respond to treatment with chemotherapy (carboplatin and pemetrexed) in combination with sotorasib or pembrolizumab for advanced/metastatic non-small cell lung cancer (NSCLC).
Aim of the study
This study will determine whether sotorasib and chemotherapy reduces the risk of your cancer getting worse and improves your survival (i.e. increases the likelihood that you will live longer) compared to the current standard treatment of pembrolizumab and chemotherapy.
Who can take part?
Patients with advanced stage NSCLC.
Procedure
If you decide to take part, you will be randomly assigned to one of 2 groups. They belong to either the test group or the control group. You will know which group you belong to. In the trial group, you will receive the study drug Sotorasib in combination with Pemetrexed and Carboplatin. In the control group, you will receive pembrolizumab in combination with pemetrexed and carboplatin.
Compensation
Original study name
A phase 3 study of first-line treatment with a platinum doublet in combination with sotorasib versus pembrolizumab in PD-L1-negative KRAS p.G12C-positive advanced/metastatic NSCLC (CodeBreaK 202)
BASEC number
2023-01104
Sponsors